SNBL’s SNLD to Present Nasal Levodopa Study at AAN 2025

The latest announcement is out from Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ).

SNBL’s subsidiary, SNLD, will present findings from a Phase II clinical study on TR-012001, a nasal levodopa therapy for Parkinson’s Disease, at the American Academy of Neurology 2025 Annual Meeting. This development highlights SNBL’s commitment to innovative treatments for PD, potentially improving management of OFF episodes and enhancing patient quality of life.

More about Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) operates in the biomedical industry, focusing on the development of novel therapies for central nervous system diseases, particularly Parkinson’s Disease (PD). A key subsidiary, SNLD, specializes in intranasal drug delivery platforms to advance treatments for PD and other neurological disorders.

YTD Price Performance: -7.73%

Average Trading Volume: 308,625

Technical Sentiment Signal: Hold

Current Market Cap: Yen64.07B

For detailed information about 2395 stock, go to TipRanks’ Stock Analysis page.